CG Oncology Analyst Price Targets - Benzinga

CG Oncology Inc

CGONNASDAQ

Trade with Public

Trade with Public

$63.00

-0.47-0.74%

Ult. Agg.: Oct 30, 9:27 AM

Panoramica Notizie Previsioni utili EventiObiettivi di prezzoDati finanziari Sentiment Azionariato Confronta Opzioni Rapporto azionario

CG Oncology Analyst Price Targets - Benzinga

CG Oncology Analyst Price Targets

Wall Street analyst price targets and consensus rating for CG Oncology (CGON).

Price Target Range — 11 Quarters

Analyst Consensus — 16 Analysts

15Buy

1Hold

Consensus RatingBuy# Analysts16Avg. Consensus PT$72Upside to Avg. PT+14.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 7, 2026	RBC Capital	Leonid Timashev	PT Cut	Outperform	$81→$79
Aug 7, 2026	Piper Sandler	Kelsey Goodwin	PT Raise	Overweight	$82→$85
Aug 7, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$82→$85
May 19, 2026	Wolfe Research	Kalpit Patel	Initiate	Peer Perform	—
May 18, 2026	HC Wainwright & Co.	Andres Y. Maldonado	Maintained	Buy	$100
May 14, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$77→$82
May 11, 2026	JP Morgan	Brian Cheng	PT Raise	Overweight	$91→$96
May 11, 2026	RBC Capital	Leonid Timashev	PT Raise	Outperform	$79→$81
May 11, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$75→$77
May 11, 2026	Wedbush	Yun Zhong	PT Raise	Outperform	$77→$80
Apr 27, 2026	RBC Capital	Leonid Timashev	PT Raise	Outperform	$73→$79
Apr 17, 2026	JP Morgan	Brian Cheng	PT Raise	Overweight	$65→$91
Apr 7, 2026	HC Wainwright & Co.	Andres Y. Maldonado	PT Raise	Buy	$80→$100
Feb 27, 2026	HC Wainwright & Co.	Andres Y. Maldonado	PT Raise	Buy	$75→$80
Feb 10, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$66→$75
Jan 21, 2026	RBC Capital	Leonid Timashev	PT Raise	Outperform	$61→$73
Jan 16, 2026	Piper Sandler	Kelsey Goodwin	PT Raise	Overweight	$55→$70
Jan 12, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$62→$66
Dec 11, 2025	Wedbush	Robert Driscoll	Initiate	Outperform	$70
Nov 24, 2025	Truist Securities	Gregory Renza	Initiate	Buy	$62

Analyst Ratings News

PRO
RBC Capital Maintains Outperform on CG Oncology, Lowers Price Target to $79

RBC Capital analyst Leonid Timashev maintains CG Oncology (NASDAQ:CGON) with a Outperform and lowers the price target from $81 to $79.

Benzinga Newsdesk

PRO
Piper Sandler Maintains Overweight on CG Oncology, Raises Price Target to $85

Piper Sandler analyst Kelsey Goodwin maintains CG Oncology (NASDAQ:CGON) with a Overweight and raises the price target from $82 to $85.

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on CG Oncology, Raises Price Target to $85

Truist Securities analyst Gregory Renza maintains CG Oncology (NASDAQ:CGON) with a Buy and raises the price target from $82 to $85.

Benzinga Newsdesk

PRO
Wolfe Research Initiates Coverage On CG Oncology with Peer Perform Rating

Wolfe Research analyst Kalpit Patel initiates coverage on CG Oncology (NASDAQ:CGON) with a Peer Perform rating.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on CG Oncology, Maintains $100 Price Target

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates CG Oncology (NASDAQ:CGON) with a Buy and maintains $100 price target.

Benzinga Newsdesk

PRO
Truist Securities Reiterates Buy on CG Oncology, Raises Price Target to $82

Truist Securities analyst Gregory Renza reiterates CG Oncology (NASDAQ:CGON) with a Buy and raises the price target from $77 to $82.

Benzinga Newsdesk